利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

17 条记录 (耗时 0.016 秒)

    Method of producing functional protein domains
    3.
    发明授权
    Method of producing functional protein domains 失效
    产生功能蛋白结构域的方法

    公开(公告)号：US08048645B2

    公开(公告)日：2011-11-01

    申请号：US10343684

    申请日：2001-08-01

    申请人： Giampiero De Luca ,  Luca Falciola

    发明人： Giampiero De Luca ,  Luca Falciola

    IPC分类号： C12N15/00 ,  C12N15/11

    CPC分类号： C12N15/10 ,  C12N15/67 ,  C12N15/907 ,  C12N2830/42 ,  C12N2840/20 ,  C12N2840/44 ,  C12P21/02

    摘要： The present invention provides a method of producing functional protein domains, which are fragments of primary translational products consisting of one or more distinct protein domains encoded by specific subsets of exonic sequences. The method is based on the integration, by a single homologous recombination event, of a regulatory unit into the eukaryotic gene coding for the primary translational product at the level of the intronic genomic region immediately adjacent to the exonic sequences which code for the functional protein domain.

    摘要翻译： 本发明提供了一种生产功能蛋白结构域的方法，其是由一个或多个不同蛋白质结构域组成的初级翻译产物的片段，其由特定的外显子序列子集编码。 该方法基于通过单个同源重组事件将调节单元整合到编码原代翻译产物的真核基因中，所述原代翻译产物在紧邻编码功能性蛋白质结构域的外显子序列的内含子基因组区域的水平 。

    COMBINATION AND TREATMENT FOR MULTIPLE SCLEROSIS
    4.
    发明申请
    COMBINATION AND TREATMENT FOR MULTIPLE SCLEROSIS 审中-公开
    多发性硬化症的组合和治疗

    公开(公告)号：US20100129353A1

    公开(公告)日：2010-05-27

    申请号：US11722487

    申请日：2005-12-20

    申请人： Giampiero De Luca

    发明人： Giampiero De Luca

    IPC分类号： A61K39/395 ,  A61K31/7076 ,  A61P21/00

    CPC分类号： A61K31/7076 ,  A61K39/39541 ,  A61K2039/505 ,  C07K16/2839 ,  C07K2317/24 ,  C07K2317/70 ,  A61K2300/00

    摘要： This invention is directed towards treatments for multiple sclerosis comprising administering to a patient in need thereof a first agent, such as 2-chloro-2′-deoxyadenosine (2-CdA), that reduces the number of lymphocytes in combination with a second agent, such as an anti-alpha-4 integrin antibody, that blocks the adhesion of monocytes and leukocytes to endothelial cells. The use of 2-CdA combined with an anti-alpha-4 integrin antibody may be more effective than either treatment alone for MS. Furthermore, the combination treatment may allow for a lowering or altering the dose of one or more of the agents in order to limit any adverse effects associated with the individual agents, but maintaining the same therapeutic efficacy.

    摘要翻译： 本发明涉及多发性硬化症的治疗，包括向有需要的患者施用第一药剂，例如与第二药物组合减少淋巴细胞数量的2-氯-2'-脱氧腺苷（2-CdA） 例如抗α-4整联蛋白抗体，其阻断单核细胞和白细胞对内皮细胞的粘附。 与抗α-4整联蛋白抗体结合使用的2-CdA可能比单独用于MS的治疗更有效。 此外，组合治疗可以允许降低或改变一种或多种药剂的剂量，以便限制与各个药剂相关的任何副作用，但是保持相同的治疗功效。

    Combined use of ribavirin and interferon beta in demyelinating diseases
    5.
    发明申请
    Combined use of ribavirin and interferon beta in demyelinating diseases 审中-公开
    在脱髓鞘疾病中联合使用利巴韦林和干扰素β

    公开(公告)号：US20060276419A1

    公开(公告)日：2006-12-07

    申请号：US10546843

    申请日：2004-02-24

    申请人： Giampiero De Luca

    发明人： Giampiero De Luca

    IPC分类号： A61K31/7056 ,  A61K38/21

    CPC分类号： A61K45/06 ,  A61K31/00 ,  A61K31/7056 ,  A61K38/215 ,  A61K2300/00

    摘要： The present invention is in the field of neurological disorders. It relates to the use of a compound of formula (I) in combination with an interferon (IFN) for the manufacture of a medicament for treatment and/or prevention of a demyelinating disease. In particular, it relates to the use of a combination of Ribavirin and IFN-beta for treatment and/or prevention of a demyelinating disease, such as multiple sclerosis.

    摘要翻译： 本发明在神经障碍领域。 它涉及式（I）化合物与干扰素（IFN）组合用于制备用于治疗和/或预防脱髓鞘疾病的药物的用途。 特别地，它涉及利巴韦林和IFN-β的组​​合在治疗和/或预防脱髓鞘疾病如多发性硬化中的应用。

    Tumor necrosis factor combined with interferon in demyelinating diseases
    9.
    发明授权
    Tumor necrosis factor combined with interferon in demyelinating diseases 失效
    肿瘤坏死因子与干扰素联合在脱髓鞘疾病中

    公开(公告)号：US07674453B2

    公开(公告)日：2010-03-09

    申请号：US10503525

    申请日：2003-01-29

    申请人： Giampiero de Luca

    发明人： Giampiero de Luca

    IPC分类号： A61K45/00 ,  A61K38/21 ,  A61K39/00 ,  A61K38/16

    CPC分类号： A61K38/191 ,  A61K31/573 ,  A61K38/02 ,  A61K38/1793 ,  A61K38/215 ,  A61K38/217 ,  A61K45/06 ,  A61K2300/00

    摘要： The invention relates to the use of an agent having, stimulating or maintaining tumor necrosis factor (TNF) activity, together with an interferon (IFN) for treating and/or preventing demyelinating diseases, in particular multiple sclerosis (MS). The use of a combination of a TNF or a tumor necrosis factor binding protein in combination with an interferon for treating and/or preventing demyelinating diseases is preferred.

    摘要翻译： 本发明涉及具有刺激或维持肿瘤坏死因子（TNF）活性的试剂与干扰素（IFN）一起用于治疗和/或预防脱髓鞘疾病，特别是多发性硬化（MS）的用途。 优选将TNF或肿瘤坏死因子结合蛋白与干扰素组合用于治疗和/或预防脱髓鞘病的用途。